The user is considering PRP with exosomes for hair loss after oral minoxidil and dutasteride failed to provide desired results. Despite suggestions for a hair transplant, the user is hesitant due to cost and complexity, and is unsure about other options.
Plant-based exosomes for hair loss lack scientific evidence and are considered high-risk with low evidence. Combining PRF with minoxidil and finasteride is suggested as a better option.
Adipose-derived stem cell secretome showed significant improvement in hair density and growth, especially when combined with minoxidil, suggesting a synergistic effect. The study had limitations, including a small sample size and potential bias.
Minoxidil can be effectively delivered through nanoemulsions containing eucalyptol or oleic acid, enhancing its diffusivity and targeting hair follicles. This contradicts the advice against mixing minoxidil with oils in topical formulations.
The conversation is about a 21-year-old using finasteride, dermarolling, ketoconazole shampoo, hair growth serums, and exosome therapy to treat early-stage thinning on the crown. They are questioning if these treatments are sufficient to improve hair thickness.
Considering exosome stem cell injections for hair loss alongside minoxidil and finasteride. Some suggest trying dutasteride first due to its proven effectiveness.
A user is seeking recommendations for dermatologists or hair clinics in the Greater Sacramento or Bay Area for exosome treatments, comparing topical application plus microneedling versus direct scalp injections. They are also asking for personal experiences and before-and-after photos.
User doing PRP with exosomes for hair loss, sees possible regrowth after two treatments. Another user suggests providing before and after pictures for better assessment.
Fatty acid metabolic signaling can activate epithelial stem cells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.
SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.
New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.
The conversation is about a 21-year-old male inquiring about the effectiveness of exosome therapy for hair thinning on the crown and considering whether to start Minoxidil while already on Finasteride and having had exosome injections 15 days ago.
The conversation is about a product called Serioxyl, which was expected to contain stemoxydine. It clarifies that Diethyl lutidinate is another name for stemoxydine.
The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.
Ethosomes are suggested as an effective delivery method for topical finasteride solutions, requiring the addition of a phospholipid like soya lecithins. The user questions why do-it-yourself solutions don't commonly use ethosomes despite their potential benefits.
The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
A user is trying 2-deoxy-D-ribose with distilled water for hair growth, observing new hair and skin pigmentation changes. Others compare it to Minoxidil, expressing interest and caution about its effectiveness and safety.
Dr. Bloxham's new channel will discuss verteporfin and other future hair loss treatments. Users express interest and hope for the effectiveness of these treatments.
Using a combination of micro-needling and exosome injections as a potential treatment for male pattern baldness, which could result in 50% or more regrowth.
Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.
New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.